News Sentiment

INAB sentiment intelligence

In8bio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.33 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+0.0% over one week, -7.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Enterprise value to EBIT forward of IN8bio, Inc. – FWB:6JH0

Market Reaction

Balanced read

53/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 0.0% Price digesting
Trend fit Trend inactive -7.0% over four weeks
Fair value -90.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 37
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 15
Market source 9
GlobeNewswire 6
TradingKey 5
Stock Titan 3
AD HOC NEWS 3
dars.gov.et 3
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 22
Analyst action 2
Regulatory and legal 1
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 53
TradingView Direct company coverage

Enterprise value to EBIT forward of IN8bio, Inc. – FWB:6JH0

The article focuses on the "Enterprise value to EBIT forward" metric for IN8bio, Inc. (FWB:6JH0) on the Frankfurt Stock Exchange. It appears to be a financial data point provided by TradingView, possibly showing the value and change over a period.

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 18:11
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of IN8bio, Inc. – DUS:6JH0

The article focuses on the "Enterprise value to EBIT forward" metric for IN8bio, Inc. (DUS:6JH0), listed on the Dusseldorf Stock Exchange. It provides a financial overview of the company's valuation, indicating market status as closed with no recent trades. The content primarily

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 18:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of IN8bio, Inc. – DUS:6JH0

This article provides the "Price to sales forward" metric for IN8bio, Inc. (DUS:6JH0) on the Dusseldorf Stock Exchange. It indicates that the market is closed with no trades recorded at the time of publication, and the content is primarily a data placeholder from TradingView.

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 12:40
Source
TradingView
Investing.com UK Direct company coverage

IN8bio publishes phase 1 glioblastoma trial results in JCO By Investing.com

IN8bio, Inc. (NASDAQ:INAB) announced the publication of clinical data from its Phase 1 trial of INB-200 for glioblastoma in The Journal of Clinical Oncology. Despite a 41% year-to-date decline in stock value, InvestingPro analysis suggests the clinical-stage biotech, with a marke

Tone
Positive 70/100
Event
Earnings
Published
12 Jul 2026 07:40
Source
Investing.com UK
Market source Direct company coverage

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

IN8bio announced the publication of peer-reviewed clinical data from its Phase 1 trial of INB-200 in The Journal of Clinical Oncology (JCO). The study demonstrates that their DeltEx™ DRI doubles progression-free survival in newly diagnosed glioblastoma patients without significan

Tone
Positive 70/100
Event
Market update
Published
09 Jul 2026 16:40
Source
Market source
GlobeNewswire Direct company coverage

IN8bio Announces Publication in The Journal of Clinical

IN8bio, Inc. announced the publication of peer-reviewed clinical data from its Phase 1 trial of INB-200 in The Journal of Clinical Oncology. The study demonstrated that its DeltEx™ DRI (Drug Resistant Immunotherapy) treatment doubled progression-free survival in newly diagnosed g

Tone
Positive 95/100
Event
Market update
Published
09 Jul 2026 11:40
Source
GlobeNewswire
AD HOC NEWS Direct company coverage

IN8bio Inc updates its immunotherapy pipeline as Nasdaq-listed biotech navigates clinical milestones

IN8bio Inc, a Nasdaq-listed clinical-stage biotechnology company, is advancing its gamma-delta T cell immunotherapy programs for various cancers. The company is navigating clinical milestones, with investors closely watching upcoming trial readouts and regulatory developments. It

Tone
Positive 71/100
Event
Regulatory and legal
Published
07 Jul 2026 11:41
Source
AD HOC NEWS
Finviz Direct company coverage

INAB - IN8bio Inc Latest SEC Filings

This article provides the latest SEC filings and comprehensive financial data for IN8bio Inc. (INAB). It details key financial metrics such as market cap, enterprise value, income, sales, per-share data, and various ratios, alongside insider ownership, institutional ownership, an

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 03:11
Source
Finviz
Ad-hoc-news.de Direct company coverage

IN8bio stock centers on clinical programs. The Nasdaq listing stays the key anchor.

IN8bio (INAB) is a clinical-stage biotechnology company focused on gamma-delta T cell therapies for cancer, with its stock trading on the Nasdaq Capital Market. The company's value is primarily driven by its clinical pipeline progress, trial milestones, and financing decisions ra

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 18:39
Source
Ad-hoc-news.de
TradingView Direct company coverage

Enterprise value to EBITDA forward of IN8bio, Inc. – NASDAQ:INAB

This page from TradingView displays financial data, specifically the Enterprise Value to EBITDA (forward) for IN8bio, Inc. (NASDAQ:INAB). The article indicates that there are no current trades and provides an overview of the company's financials for investors and analysts.

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 13:11
Source
TradingView
TradingView Direct company coverage

INAB Forecast — Price Target — Prediction for 2027

This article provides a forecast for IN8bio, Inc. (INAB), including analyst price targets and predictions for 2027. It details the stock's current price, performance, volatility, market capitalization, and upcoming earnings report. The piece also includes frequently asked questio

Tone
Neutral 50/100
Event
Analyst action
Published
27 Jun 2026 00:09
Source
TradingView
TradingView Direct company coverage

6JH0 Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for IN8bio, Inc. (6JH0) for 2027, based on analyst opinions. It includes information on the stock's historical performance, earnings reports, revenue, net income, employee count, and answers frequently asked questions about buying

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 11:10
Source
TradingView
TradingView Direct company coverage

IN8bio, Inc. Actuals & Estimates (NASDAQ:INAB)

This article provides key financial data and analyst estimates for IN8bio, Inc. (NASDAQ:INAB), including its current stock price, recent performance declines, and future price forecasts. It details the company's financial results, such as recent earnings and revenue, market capit

Tone
Negative 39/100
Event
Earnings
Published
26 Jun 2026 11:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of IN8bio, Inc. – SWB:6JH0

This article provides financial information for IN8bio, Inc. (SWB:6JH0), specifically focusing on its Enterprise Value to EBITDA forward metric. The data is sourced from FactSet Research Systems Inc. and ICE Data Services.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 08:09
Source
TradingView
TradingView Direct company coverage

IN8bio, Inc. Actuals & Estimates (FWB:6JH0)

This article provides an overview of IN8bio, Inc. (FWB:6JH0) financials and analyst estimates, including price targets, historical highs and lows, and upcoming earnings dates. It details the company's past quarterly earnings and revenue, noting that IN8bio does not pay dividends

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 06:09
Source
TradingView
TradingView Direct company coverage

IN8bio, Inc. Actuals & Estimates (SWB:6JH0)

This article provides financial actuals and estimates for IN8bio, Inc. (SWB:6JH0), including income statement, balance sheet, and cash flow data, along with analyst price targets and future earnings expectations. It outlines key financial figures like earnings per share and reven

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 05:09
Source
TradingView
TradingView Direct company coverage

Price to book forward of IN8bio, Inc. – NASDAQ:INAB

This article focuses on the "Price to book forward" metric for IN8bio, Inc. (NASDAQ: INAB). It presents a data point within the context of the company's financial overview on the TradingView platform, with no other detailed information provided.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 02:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of IN8bio, Inc. – SWB:6JH0

This article provides the enterprise value to EBIT forward for IN8bio, Inc. (SWB:6JH0) on the Stuttgart Stock Exchange. It indicates that the financial data is specifically for "Enterprise value to EBIT forward" for the company. The page also lists various general sections of the

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 18:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of IN8bio, Inc. – NASDAQ:INAB

This article provides the enterprise value to revenue forward for IN8bio, Inc. (NASDAQ: INAB). It appears to be a financial data snippet from TradingView, indicating the value and any changes for this specific ratio. No further details or analysis are present in the provided cont

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 18:41
Source
TradingView
TradingKey Direct company coverage

IN8BIO, Inc. (INAB) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of IN8BIO, Inc. (INAB), focusing on its profitability and balance sheet. However, the analysis states that relevant financial data for profitability metrics such as cash and cash equivalents, total assets, total liabilities, free

Tone
Neutral 50/100
Event
Balance sheet
Published
17 Jun 2026 22:40
Source
TradingKey
TradingKey Direct company coverage

IN8BIO, Inc. (INAB) Institutional Confidence

This article reports on the institutional confidence in IN8BIO, Inc. (INAB), detailing key institutional shareholdings and changes in their positions. It lists prominent investment groups and individuals, along with the number of shares held and the percentage change in their hol

Tone
Positive 61/100
Event
Market update
Published
17 Jun 2026 22:40
Source
TradingKey
TradingKey Direct company coverage

IN8BIO, Inc. (INAB) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for IN8BIO, Inc. (INAB), detailing analyst ratings, price targets, and past and future EPS expectations. Based on 4 analysts, the consensus rates INAB as a "Buy" with a target price of USD 7.00, suggesting a significant upside. The repor

Tone
Positive 71/100
Event
Earnings
Published
17 Jun 2026 17:40
Source
TradingKey
TradingKey Direct company coverage

IN8BIO, Inc. (INAB) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for IN8BIO, Inc. (INAB), focusing on its PE, PB, P/S, and P/CF ratios. It highlights that relevant data for these valuation metrics have not yet been disclosed by the company. The stock is currently trading at $1.420 USD, up 2.90%.

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 17:39
Source
TradingKey
TradingKey Direct company coverage

IN8BIO, Inc. (INAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for IN8BIO, Inc. (INAB) but states that relevant business segment and regional revenue data have not been disclosed by the company yet. Despite the lack of specific financial details, the page displays INAB's cu

Tone
Neutral 50/100
Event
Earnings
Published
16 Jun 2026 03:40
Source
TradingKey
GlobeNewswire Direct company coverage

IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026

IN8bio presented updated clinical data at ASCO 2026 for its DeltEx DRI therapy in newly diagnosed glioblastoma, showing a median progression-free survival of 13.0 months and median overall survival exceeding 19.5 months in repeat-dose patients. These results significantly surpass

Tone
Positive 74/100
Event
Earnings
Published
15 Jun 2026 18:11
Source
GlobeNewswire